Colorectal cancer (CCR) is the third most common cancer worldwide in men and women,
the second largest cause of death related to cancer, and the main cause of death in …

Predictive biomarkers are becoming increasingly important tools in drug development and
clinical research. The importance of using both guidelines for specimen acquisition and …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Next-generation sequencing of cell-free circulating solid tumor DNA addresses two
challenges in contemporary cancer care. First this method of massively parallel and deep …

Purpose: Epidermal growth factor receptor (EGFR) antibody therapy is established in
patients with wild-type KRAS colorectal carcinoma; however, up to 50% of these patients do …

Background: KRAS mutation is a negative predictive factor for treatment with anti-epidermal
growth factor receptor antibody in metastatic colorectal cancer (CRC). KRAS mutation …

Purpose To compare the mutational and copy number profiles of primary and metastatic
colorectal carcinomas (CRCs) using both unpaired and paired samples derived from …

BRAFV600E mutations are found in 10% of colorectal cancers (CRCs). The low frequency of
this mutation therefore makes it a challenging target for drug development, unless subsets of …

The epidermal growth factor receptor (EGFR) plays an important role in tumorigenesis and
tumor progression of colorectal cancer (CRC). As a result, the EGFR has evolved as a …

Colorectal cancer (CRC) is characterized by recurrent mutations deregulating key cell
signaling cascades and providing the cancer cells with novel functional traits. Among the …